Phosphodiesterase-5 Inhibitors in Reversal of Male Infertility: A Meta-analysis
Article Sidebar
Main Article Content
Abstract
The prevalence of male infertility is an increasing concern in the domain of public health, impacting a substantial number of men globally. Phosphodiesterase-5 (PDE-5) Inhibitors primarily used for the treatment of erectile dysfunction. This Meta-analysis has been done to investigate the success rate of the drug Phosphodiesterase-5 Inhibitors therapies in reversal of infertility in the men. We conducted an extensive review of multiple databases to gather research examining effects of diverse pharmacological agents on male fertility factors. Our selection focused on robust study design, namely randomized controlled trials, observational studies, and clinical trials, which evaluated the success of the drugs relative to placebos or no treatment. To perform Meta-analysis total number of 220 research papers were systematically reviewed; apart from the 220 research papers 20 showed more similarity to our topic efficacy of drug Phosphodiesterase-5 Inhibitors in the reversal of male infertility. This Meta-analysis suggests that Phosphodiesterase-5 Inhibitors can positively impact in the treatment of erectile dysfunction. These findings indicate that Phosphodiesterase-5 Inhibitors may be a valuable therapeutic option for certain types of male infertility. This meta-analysis offers a comprehensive synthesis of current evidence and suggests areas for future research to confirm drug Phosphodiesterase-5 Inhibitors role in the treatment of male infertility.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Afsar, B., Ortiz, A., Covic, A., Gaipov, A., Esen, T., Goldsmith, D., & Kanbay, M. (2015). Phosphodiesterase type 5 inhibitors and kidney disease. International urology and nephrology, 47, 1521-1528.
Aversa, A., Bruzziches, R., Pili, M., & Spera, G. (2006). Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Current pharmaceutical design, 12(27), 3467-3484.
Aversa, A., Mazzilli, F., Rossi, T., Delfino, M., Isidori, A. M., & Fabbri, A. (2000). Effects of sildenafil (Viagra™) administration on seminal parameters and post-ejaculatory refractory time in normal males. Human Reproduction, 15(1), 131-134.
Aversa, A., Pili, M., Francomano, D., Bruzziches, R., Spera, E., La Pera, G., & Spera, G. (2009). Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. International Journal of Impotence Research, 21(4), 221-227.
Buvat, J., Montorsi, F., Maggi, M., Porst, H., Kaipia, A., Colson, M. H., ... & Shabsigh, R. (2011). Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). The journal of sexual medicine, 8(1), 284-293
Campbell, H. E. (2005). Clinical monograph for drug formulary review: erectile dysfunction agents. Journal of Managed Care Pharmacy, 11(2), 151-171.
Chowdhury, S. R., Karim, M., Ullah, S. A., & Bakar, M. A. (2019). Association between erectile dysfunction and cardiovascular disease: A systematic review. Chattagram Maa-O-Shishu Hospital Medical College Journal, 18(2), 59-66.
Dimitriadis, F., Tsambalas, S., Tsounapi, P., Kawamura, H., Vlachopoulou, E., Haliasos, N., ... & Sofikitis, N. (2010). Effects of phosphodiesterase‐5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU international, 106(8), 1181-1185.
Gökçe, A., Halis, F., Demirtas, A., & Ekmekcioglu, O. (2011). The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double‐blind laboratory setting study. BJU international, 107(8), 1274-1277.
Goldstein, I., McCullough, A. R., Jones, L. A., Hellstrom, W. J., Bowden, C. H., DiDonato, K., ... & Day, W. W. (2012). A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. The journal of sexual medicine, 9(4), 1122-1133.
Heitman, J., Sun, S., & James, T. Y. (2013). Evolution of fungal sexual reproduction. Mycologia, 105(1), 1-27.
Hellstrom, W. J., Gittelman, M., Jarow, J., Steidle, C., McMurray, J., Talley, D., ... & McGill, J. M. (2008). An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. European urology, 53(5), 1058-1065.
Hellstrom, W. J., Kaminetsky, J., Belkoff, L. H., Goldstein, I., Tursi, J. P., Uy, J., ... & Day, W. W. (2015). Efficacy of avanafil 15 minutes after dosing in men with erectile dysfunction: a randomized, double-blind, placebo controlled study. The Journal of Urology, 194(2), 485-492.
Hellstrom, W. J., Overstreet, J. W., Yu, A., Saikali, K., Shen, W. E. I., Beasley, C. M., & Watkins, V. S. (2003). Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. The Journal of urology, 170(3), 887-891.
Isidori, A. M., Buvat, J., Corona, G., Goldstein, I., Jannini, E. A., Lenzi, A., ... & Maggi, M. (2014). A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment—a systematic review. European urology, 65(1), 99-112.
La Vignera, S. (2013). Seminal vesicles of infertile patients with male accessory gland infection: ultrasound evaluation after prolonged treatment with tadalafil, a selective phosphodiesterase‐5 inhibitor. Andrologia, 45(6), 386-391.
Leaver, R. B. (2016). Male infertility: an overview of causes and treatment options. British Journal of Nursing, 25(18), S35-S40.
Levine, H., Jørgensen, N., Martino-Andrade, A., Mendiola, J., Weksler-Derri, D., Mindlis, I., ... & Swan, S. H. (2017). Temporal trends in sperm count: a systematic review and meta-regression analysis. Human reproduction update, 23(6), 646-659.
Lombardi, G., Nelli, F., Celso, M., Mencarini, M., & Del Popolo, G. (2012). Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. The Journal of Sexual Medicine, 9(4), 970-985.
Lue, T. F. (2000). Erectile dysfunction. New England journal of medicine, 342(24), 1802-1813.
Mateu, E., Rodrigo, L., Martínez, M. C., Peinado, V., Milán, M., Gil-Salom, M., ... & Rubio, C. (2010). Aneuploidies in embryos and spermatozoa from patients with Y chromosome microdeletions. Fertility and sterility, 94(7), 2874-2877.
Mattos, R. M., Marmo Lucon, A., & Srougi, M. (2008). Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia internationalis, 80(2), 162-165.
McCabe, M., Althof, S. E., Assalian, P., Chevret-Measson, M., Leiblum, S. R., Simonelli, C., & Wylie, K. (2010). Psychological and interpersonal dimensions of sexual function and dysfunction. The journal of sexual medicine, 7(1_Part_2), 327-336.
McMahon, C. G., Stuckey, B. G., Andersen, M., Purvis, K., Koppiker, N., Haughie, S., & Boolell, M. (2005). Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. The journal of sexual medicine, 2(3), 368-375.
Montorsi, F., Padma‐Nathan, H., Buvat, J., Schwaibold, H., Beneke, M., Ulbrich, E., ... & Porst, H. (2004). Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at‐home setting: A randomized, double‐blind, placebo‐controlled trial. The Journal of Sexual Medicine, 1(2), 168-178.
Mostafa, T. (2008). Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. The journal of sexual medicine, 5(11), 2502-2518.
Olayemi, F. O. (2010). Review on some causes of male infertility. African Journal of Biotechnology, 9(20).
Park, H. J., Kim, S. W., Kim, J. J., Lee, S. W., Paick, J. S., Ahn, T. Y., ... & Park, N. C. (2017). A randomized, placebo-controlled, double-blind, multi-center therapeutic confirmatory study to evaluate the safety and efficacy of avanafil in Korean patients with erectile dysfunction. Journal of Korean Medical Science, 32(6), 1016-1023.
Potts, A., Grace, V. M., Vares, T., & Gavey, N. (2006). ‘Sex for life’? Men's counter‐stories on ‘erectile dysfunction’, male sexuality and ageing. Sociology of Health & Illness, 28(3), 306-329.
Prendergast, M. L., Podus, D., Chang, E., & Urada, D. (2002). The effectiveness of drug abuse treatment: A meta-analysis of comparison group studies. Drug and alcohol dependence, 67(1), 53-72.
Sedlander, E., Bingenheimer, J. B., Thiongo, M., Gichangi, P., Rimal, R. N., Edberg, M., & Munar, W. (2018). “They destroy the reproductive system”: exploring the belief that modern contraceptive use causes infertility. Studies in family planning, 49(4), 345-365.
Shabsigh, R., Kaufman, J. M., Steidle, C., & Padma-Nathan, H. (2008). Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. The Journal of urology, 179(5), S97-S102.
Shamloul, R., Ghanem, H., Fahmy, I., El‐Meleigy, A., Ashoor, S., Elnashaar, A., & Kamel, I. (2005). Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. The journal of sexual medicine, 2(4), 559-564.
Song, S. H., Shin, D. H., Her, Y. S., Oh, M. H., Baek, J. W., Sung, S., ... & Kim, D. S. (2021). Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study. Investigative and Clinical Urology, 62(3), 354.
Tsounapi, P., Honda, M., Dimitriadis, F., Koukos, S., Hikita, K., Zachariou, A., ... & Takenaka, A. (2018). Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: a randomised controlled trial. Andrologia, 50(8), e13071.
Upadhyay, Y., Chhabra, A., & Nagar, J. C. (2020). A women infertility: an overview. Asian Journal of Pharmaceutical Research and Development, 8(2), 99-106.
Yang, C., Li, P., & Li, Z. (2022). Clinical application of aromatase inhibitors to treat male infertility. Human Reproduction Update, 28(1), 30-50.
Yassin, A. A., Saad, F., & Diede, H. E. (2006). Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: Results from an open‐label uncontrolled study. Andrologia, 38(2), 61-68.
Zhang, J., Yang, B., Cai, Z., Li, H., Han, T., & Wang, Y. (2019). The negative impact of higher body mass index on sperm quality and erectile function: a cross-sectional study among Chinese males of infertile couples. American Journal of Men's Health, 13(1), 1557988318822572.